Association between genetic polymorphisms of Macrophage scavenger receptor 1 gene and risk of prostate cancer in the health professionals follow-up study

被引:4
作者
Chen, Yen-Ching [1 ,5 ,6 ]
Giovannucci, Edward [1 ,3 ,4 ]
Kraft, Peter [2 ]
Hunter, David J. [1 ,3 ,4 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Program Mol & Genet Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[5] Natl Taiwan Univ, Res Ctr Genes Environm & Human Hlth, Taipei 10764, Taiwan
[6] Natl Taiwan Univ, Grad Inst Epidemiol, Coll Publ Hlth, Taipei 10764, Taiwan
关键词
D O I
10.1158/1055-9965.EPI-07-0744
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Macrophage scavenger receptor 1 (MSR1) is involved in chronic inflammation, which is a risk factor for prostate cancer. Association studies assessing the relationship between sequence variants of MSR1 and prostate cancer are inconsistent. We hypothesized that sequence variants of MSR1 were associated with prostate cancer risk. Methods: In a nested case-control design within the Health Professionals Follow-up Study, we identified 700 participants with prostate cancer diagnosed after they had provided a blood specimen in 1993 and before January 2000. Controls were 700 age-matched men without prostate cancer who had had a prostate-specific antigen test after providing a blood specimen. We genotyped three common (>5%) single nucleotide polymorphisms (SNP) that have been reported previously to be associated with risk of prostate cancer. Results: None of these MSR1 SNPs nor estimated haplotypes were associated with prostate cancer risk (P for the global test for haplotypes = 0.89). These MSR1 SNPs also did not appear to be associated with higher-grade or advanced-stage prostate cancer. Conclusion: The association between these sequence variants of MSR1 and the risk of prostate cancer was null. Further study of aggressive prostate cancer may be warranted, as we had limited power to assess these.
引用
收藏
页码:1001 / 1003
页数:3
相关论文
共 21 条
[1]
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases [J].
Casey, G ;
Neville, PJ ;
Plummer, SJ ;
Xiang, Y ;
Krumroy, LM ;
Klein, EA ;
Catalona, WJ ;
Nupponen, N ;
Carpten, JD ;
Trent, JM ;
Silverman, RH ;
Witte, JS .
NATURE GENETICS, 2002, 32 (04) :582-583
[2]
Chen H, 2003, J Med Genet, V40, pe21, DOI 10.1136/jmg.40.3.e21
[3]
Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer [J].
Chen, YC ;
Giovannucci, E ;
Lazarus, R ;
Kraft, P ;
Ketkar, S ;
Hunter, DJ .
CANCER RESEARCH, 2005, 65 (24) :11771-11778
[4]
EMI M, 1993, J BIOL CHEM, V268, P2120
[5]
Assessing the impact of population stratification on genetic association studies [J].
Freedman, ML ;
Reich, D ;
Penney, KL ;
McDonald, GJ ;
Mignault, AA ;
Patterson, N ;
Gabriel, SB ;
Topol, EJ ;
Smoller, JW ;
Pato, CN ;
Pato, MT ;
Petryshen, TYL ;
Kolonel, LN ;
Lander, ES ;
Sklar, P ;
Henderson, B ;
Hirschhorn, JN ;
Altshuler, D .
NATURE GENETICS, 2004, 36 (04) :388-393
[6]
TYPE-I MACROPHAGE SCAVENGER RECEPTOR CONTAINS ALPHA-HELICAL AND COLLAGEN-LIKE COILED COILS [J].
KODAMA, T ;
FREEMAN, M ;
ROHRER, L ;
ZABRECKY, J ;
MATSUDAIRA, P ;
KRIEGER, M .
NATURE, 1990, 343 (6258) :531-535
[7]
Analysis of the macrophage scavenger receptor I gene in Swedish hereditary and sporadic prostate cancer [J].
Lindmark, F ;
Jonsson, BA ;
Bergh, A ;
Stattin, P ;
Zheng, SL ;
Meyers, DA ;
Xu, JF ;
Grönberg, H .
PROSTATE, 2004, 59 (02) :132-140
[8]
Germline mutations of the MSR1 gene in prostate cancer families from Germany [J].
Maier, C ;
Vesovic, Z ;
Bachmann, N ;
Herkommer, K ;
Braun, AK ;
Surowy, HM ;
Assum, G ;
Paiss, T ;
Vogel, W .
HUMAN MUTATION, 2006, 27 (01) :98-102
[9]
Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene [J].
Maier, C ;
Haeusler, J ;
Herkommer, K ;
Vesovic, Z ;
Hoegel, J ;
Vogel, W ;
Paiss, T .
BRITISH JOURNAL OF CANCER, 2005, 92 (06) :1159-1164
[10]
Miller DC, 2003, CANCER RES, V63, P3486